Biopharmaceutical company Celgene Corp. said Thursday its board has approved an additional $4 billion buyback of its common stock. The program will add to the $5.2 billion still remaining in previous approvals, the company said in a statement. Shares were not yet active in premarket trade, but are down 0.7% in the year so far, while the S&P 500 has gained 1.8%.
Copyright © 2015 MarketWatch, Inc.
Continue Reading Below